Lung Cancer SPORE Workshop  
Meeting Agenda  
June 13-14, 2019

7:45 AM  Opening Remarks  
Peter Ujhazy

Thursday, June 13, 2019  
New SPORES  
Moderator: Peter Ujhazy

8:00 AM  FHCRC New Lung Cancer SPORE  
McGarry Houghton

8:20 AM  Emory New Lung Cancer SPORE  
Taofeek Owonikoko

Session 1 - KRAS, LKB1, and Related Pathways  
Moderator: Ferdinandos Skoulidis, MDACC

8:40 AM  LKB1 Deficiency and KEAP1/NRF2 Pathway Alterations as Biomarkers of  
Response for ATR and ATM Inhibitors and Other Inhibitors of DNA Damage  
Response (DDR) in NSCLC  
Ana Galan-Cobo

8:55 AM  Lactate Transporter Blockade as a Strategy to Overcome VEGF Inhibitor-  
Resistance in LKB1-deficient NSCLC  
Irene Guijarro

9:10 AM  MDM2 Inhibition Combined with MEK Inhibition Induces Tumor Regression and  
Growth Inhibition in Non-Small Cell Lung Cancer (NSCLC) Patient Derived  
Xenografts (PDXs) with Wild Type TP53 and Mutant KRAS  
Bingliang Fang

9:25 AM  STK11/LKB1 Genomic Alterations Are Associated with Lack of Benefit from  
Addition of Pembrolizumab to Platinum Doublet Chemotherapy in Non- 
Squamous Non-Small Cell Lung Cancer  
Ferdinandos Skoulidis

9:40 AM  Development of Multi-Cell Type Organoid Cultures for Preclinical Studies of  
Immunotherapeutics for Lung Cancer  
Josiah Flaming

9:55 AM  Epithelial Progenitor Dysfunction Sets the Stage for Squamous Cell Lung Cancer  
York Miller

10:10 AM  Depletion of Myeloid-derived Suppressor Cells (MDSCs) Overcomes Anti-PD-1  
Resistance in a Murine Model of LKB1-deficient Non Small Cell Lung Cancer  
(RSCLC)  
Rui Li

10:25 AM  Panel Discussion

10:35 AM  Break

Session 2 - Immunotherapy  
Moderator: Kathryn O’Donnell

10:55 AM  Efficacy of Novel Immunogene-Combinations for Kras and LKB1 Mutant NSCLC in  
a Humanized Mouse Model  
Ismail M Meraz

11:10 AM  In situ Vaccination with CCL21-modified Dendritic Cells (CCL21-DC) Combined  
with Checkpoint Blockade in Murine Models of NSCLC  
Raymond John Lim

11:25 AM  The Integrated Stress Response Pathway Controls PD-L1 Translation in Lung  
Cancer  
Kathryn O’Donnell

11:40 AM  Phase 1/1b Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non- 
Small Cell Lung Cancer  
James Saller
11:55 AM  Variation in the Assessment of Immune-related Adverse Event Occurrence, Type, Grade, and Timing  

12:10 PM  Systemic Immune Dysfunction in Cancer Patients Driven by IL6 and IL8 Induction of an Inhibitory Receptor Module  

12:25 PM  Panel Discussion  

12:35 PM  Lunch on Your Own  

1:45 PM  Putting the Patient Perspective into Translational Research  

2:15 PM  Analysis of the Sensitivity of EGFR and HER2 Exon 20 Mutations Identifies Poziotinib as a Potent and Selective Inhibitor of Exon 20 Mutations and An Enhancer of T-DM1  

2:45 PM  EGFR Mutations Promote Hypoxia-Independent Upregulation of HIF-1α and VEGF and a VEGF-dependent Phenotype  

2:30 PM  T790M-independent EGFR TKI Resistance is Associated with a Broad Multi-Drug Resistant Phenotype but Selective Vulnerabilities to Spindle Assembly Complex (SAC) and CDK Inhibitors  

3:00 PM  Panel Discussion  

3:10 PM  Break  

3:40 PM  Adaptive Mechanisms of Resistance to Targeted Therapy in EGFR Mutant Brain Metastasis  

3:55 PM  BRG1 as a Mediator of Resistance to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma  

4:10 PM  Resistance to Targeted Therapies as a Gradual Adaptation to Inhibitor Specific Selective Pressures  

4:25 PM  Combinatorial Therapeutic Approaches to Treat NRF2/KEAP1 Mutant NSCLC  

4:40 PM  Panel Discussion  

4:50 PM  Adjourn
**Lung Cancer SPORE Workshop**  
**Meeting Agenda**  
**June 13-14, 2019**

---

### Session 5 - Premalignancy, Risk Stratification, and Chemoprevention  
**Moderator: Steve Dubinett**

#### Friday, June 14, 2019

**8:45 AM**  
**8:00AM**

**9:00 AM**

**9:15 AM**

**9:30 AM**

**9:45 AM**

**10:00 AM**

**10:10 AM**

---

### Session 6 - Novel Targets  
**Moderator: Jerry Shay**

#### Friday, June 14, 2019

**10:30 AM**

**10:45 AM**

**11:00 AM**

---

### Session 7 - Molecular Profiling and Biomarkers  
**Moderator: Rex Yung**

#### Friday, June 14, 2019

**11:10 AM**

---

**Keynote Speaker: Lieping Chen**

**8:00am**

**A Systematic Approach to Unfold Lung Cancer Resistance to Immunotherapy**

---

**Dinner Session @ Hilton Rockville**

**How It All Started: Reminiscing the Beginning of Lung Cancer SPOREs**

**John Minna, Jack Roth, Paul Bunn, York Miller**

**6:30 PM - Dinner is Served**

**7:15 PM - Dinner Program**

---

**Panel Discussion**

**A Combined Imaging, Blood, and Clinical Biomarker Strategy for Lung Cancer Risk Reclassification in Patients with Indeterminate Pulmonary Nodules**  
**Michael Kammer**

**A Human Bronchial Epithelial Cell Model Demonstrates a Role for Glutamine Metabolism in DNA Damage and Oncogenic Transformation**  
**Pierre Massion**

**SGLT2 is a Diagnostic and Therapeutic Target for Early Stage Lung Adenocarcinoma**  
**Claudio Scafoglio**

**The Genomic Landscape and Immune Contexture of Lung Adenomatous Premalignancy**  
**Linh Tran**

**Panel Discussion**

---

**Break**

---

**Anastasios Dimou**

**Therapeutic Targeting of Telomeres Induces Replication Stress Vulnerabilities in Lung Cancer**

---

**Michael Kammer**

**Inhibition of RUVBL1/2 Causes Replication Catastrophe and Synergizes with Ionizing Radiation in Non-Small Cell Lung Cancer**

---

**Paul Yenerall**

**Claudio Scafoglio**

**Identifying Metabolic Programs in Human Lung Cancer That Indicate Tumor Aggressiveness**

---

**Brandon Faubert**

---
Lung Cancer SPORE Workshop  
Meeting Agenda  
June 13-14, 2019  

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:25 AM</td>
<td>Lung Cancer Prognosis Modeling Via Integrating Omics and Histopathological Imaging Data</td>
<td>Shuangge Ma</td>
</tr>
<tr>
<td>11:40 AM</td>
<td>In vivo Imaging of Mitochondrial Membrane Potential in Non-Small Cell Lung Cancer</td>
<td>Milica Momcilovic</td>
</tr>
<tr>
<td>11:55 AM</td>
<td>Increased Frequency of Bystander T cells in the Lungs is Associated with Recurrence in NSCLC</td>
<td>Alexandre Reuben</td>
</tr>
<tr>
<td>12:10 PM</td>
<td>ISH Chromogenic Staining of Non-coding Nascent RNA for Detection of Lung Cancer Imprinting Genes</td>
<td>Rex Yung</td>
</tr>
<tr>
<td>12:25 PM</td>
<td>Panel Discussion</td>
<td></td>
</tr>
<tr>
<td>12:35 PM</td>
<td><strong>Break</strong></td>
<td></td>
</tr>
<tr>
<td>1:45 PM</td>
<td>Targeting Jumonji Proteins for Therapeutic in SCLC</td>
<td>Aiden Nguyen</td>
</tr>
<tr>
<td>2:00 PM</td>
<td>Drug Combinations in SCLC Complex Spheroids in Culture</td>
<td>Beverly Teicher</td>
</tr>
<tr>
<td>2:15 PM</td>
<td>Clinical and Genomic Characteristics of Small Cell Lung Cancer in Never-smokers</td>
<td>Anish Thomas</td>
</tr>
<tr>
<td>2:30 PM</td>
<td>Quantitative Proteomic Analysis Identifies IGFBP5 as a Secreted Marker for ASCL1High Pulmonary Neuroendocrine Tumors</td>
<td>Xu-Dong Wang</td>
</tr>
<tr>
<td>2:45 PM</td>
<td>Panel Discussion</td>
<td></td>
</tr>
<tr>
<td>2:55 PM</td>
<td>Use and Perceptions of Electronic Nicotine Delivery Systems Among Patients Attending Lung Cancer Screening</td>
<td>Krysten Bold</td>
</tr>
<tr>
<td>3:10 PM</td>
<td>Computational Staining of Pathology Images to Study Tumor Microenvironment in Lung Cancer</td>
<td>Shidan Wang</td>
</tr>
<tr>
<td>3:25 PM</td>
<td>Tumor-growth Modeling for Informed Go/No-go Decisions</td>
<td>Wei Wei</td>
</tr>
<tr>
<td>3:40 PM</td>
<td>Panel Discussion</td>
<td></td>
</tr>
<tr>
<td>3:50 PM</td>
<td><strong>Adjournment</strong></td>
<td></td>
</tr>
</tbody>
</table>